It is of interest to note that in the Canakinumab Antiinflammatory Thrombosis Outcome Study (CANTOS), decreases in IL-6 were associated with the observed clinical benefit both in terms of MACE and cancer, and it is not surprising that IL-6 targeting is now being pursued in atherosclerosis (22). The gene discussed is IL6; the disease is Venous thrombosis.